Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Tiffany R Keepers"'
Autor:
Peter B Madrid, Sidharth Chopra, Ian D Manger, Lynne Gilfillan, Tiffany R Keepers, Amy C Shurtleff, Carol E Green, Lalitha V Iyer, Holli Hutcheson Dilks, Robert A Davey, Andrey A Kolokoltsov, Ricardo Carrion, Jean L Patterson, Sina Bavari, Rekha G Panchal, Travis K Warren, Jay B Wells, Walter H Moos, Raelyn L Burke, Mary J Tanga
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60579 (2013)
BACKGROUND: The rapid development of effective medical countermeasures against potential biological threat agents is vital. Repurposing existing drugs that may have unanticipated activities as potential countermeasures is one way to meet this importa
Externí odkaz:
https://doaj.org/article/8f664db31ceb45f1adcae9b7d13042df
Autor:
Tiffany R Keepers, Suzannah M. Schmidt-Malan, Robin Patel, Alisa W Serio, Melissa J. Karau, Bobbi S. Pritt, Surya Chitra, Scott A. Cunningham, Jayawant N. Mandrekar
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than sali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6cd17f1f9be1a4a307d5aabb13ab21e
http://europepmc.org/articles/PMC8765317
http://europepmc.org/articles/PMC8765317
Autor:
Danielle A, Nicklas, Emily C, Maggioncalda, Elizabeth, Story-Roller, Benjamin, Eichelman, Chavis, Tabor, Alisa W, Serio, Tiffany R, Keepers, Surya, Chitra, Gyanu, Lamichhane
Publikováno v:
Antimicrobial Agents and Chemotherapy
The incidence of nontuberculous mycobacterial diseases in the United States is rising and has surpassed that of tuberculosis. Most notable among the nontuberculous mycobacteria is Mycobacteroides abscessus, an emerging environmental opportunistic pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4952568e6ea346377a52df5773b7f2df
https://pubmed.ncbi.nlm.nih.gov/34662184
https://pubmed.ncbi.nlm.nih.gov/34662184
Autor:
Ian A. Critchley, Kevin M. Krause, M. A. Gómez, Chris Celeri, Tiffany R. Keepers, Donald Biek
Publikováno v:
Infectious Diseases and Therapy
Introduction Fosfomycin is a broad-spectrum cell wall active agent that inhibits the MurA enzyme involved in peptidoglycan synthesis and is FDA-approved for treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli and Ent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33226f192e930d0ad2f0b7818a988a3b
https://doi.org/10.1007/s40121-017-0150-5
https://doi.org/10.1007/s40121-017-0150-5
Autor:
Florian M E, Wagenlehner, Daniel J, Cloutier, Allison S, Komirenko, Deborah S, Cebrik, Kevin M, Krause, Tiffany R, Keepers, Lynn E, Connolly, Loren G, Miller, Ian, Friedland, Jamie P, Dwyer, Robert, Poirier
Publikováno v:
The New England journal of medicine. 380(8)
The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f420104a5ea4dd1ccf657b1feac3c6
https://pubmed.ncbi.nlm.nih.gov/31398750
https://pubmed.ncbi.nlm.nih.gov/31398750
Publikováno v:
EcoSal Plus. 8(1)
Aminoglycosides are cidal inhibitors of bacterial protein synthesis that have been utilized for the treatment of serious bacterial infections for almost 80 years. There have been approximately 15 members of this class approved worldwide for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9fca3bdd18dfc13582c2fbd21223ec
https://pubmed.ncbi.nlm.nih.gov/30447062
https://pubmed.ncbi.nlm.nih.gov/30447062
Publikováno v:
Open Forum Infectious Diseases
Plazomicin is an aminoglycoside that was approved in June 2018 by the US Food and Drug Administration for the treatment of complicated urinary tract infections, including pyelonephritis, due to Escherichia coli, Klebsiella pneumoniae, Enterobacter cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d46e41eefb99da8bd3c758dfcb85e058
https://pubmed.ncbi.nlm.nih.gov/30968059
https://pubmed.ncbi.nlm.nih.gov/30968059
Publikováno v:
International Scholarly Research Notices
Effects of varying in vitro susceptibility testing parameters of the broth microdilution assay on ceftazidime-avibactam MICs were determined and compared to meropenem and piperacillin-tazobactam for 9 Enterobacteriaceae and 4 Pseudomonas aeruginosa i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9692c5cee95f0809749423fa7d1a942c
https://doi.org/10.1155/2015/489547
https://doi.org/10.1155/2015/489547
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:5297-5305
Avibactam, a non-β-lactam β-lactamase inhibitor with activity against extended-spectrum β-lactamases (ESBLs), KPC, AmpC, and some OXA enzymes, extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms producing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c6b7bf7381211782ce32df6e6763feb
https://doi.org/10.1128/aac.02894-14
https://doi.org/10.1128/aac.02894-14
Autor:
Kevin M. Krause, Allison Seiko Komirenko, Lynn E. Connolly, Tiffany R. Keepers, Daniel J Cloutier, Deborah S Cebrik
Publikováno v:
Open Forum Infectious Diseases
Background PLZ is a next-generation aminoglycoside (AG) that is structurally protected from common AG-modifying enzymes (AMEs) in Enterobacteriaceae and with in vitro activity against multidrug-resistant Enterobacteriaceae, including ESBL-producing,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90bb3f59026e8b03a1d7a6c43920b111
http://europepmc.org/articles/PMC6253087
http://europepmc.org/articles/PMC6253087